Table 122Sensitivity analysis varying the time horizon

Year 1Year 2Year 5Year 10Year 20
Strategy 1£396.30£764£1,591£2,583£3,672
Strategy 2£469£568£775£1,126£1,585
Strategy 3 a (low risk)£201£246£493£844£1,086
Strategy 3 b (high risk)£334£426£1,070£1,635£2,310
Strategy 4 a (low risk)£463£588£1,297£1,628£1,957
Strategy 4 b (high risk)£463£760£1,751£2,293£2,960

From: 14, Monitoring and surveillance protocols

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.